WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) said that it expects its full year 2021 non-GAAP operating loss to be substantially improved relative to the prior year.
As of on December 31, 2021, Alnylam had preliminary cash, cash equivalents, and marketable securities of about $2.4 billion, compared to $1.9 billion at December 31, 2020.
The company reported 2021 preliminary global net product revenues of $662 million, representing a 83% annual growth compared to 2020.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX